Strange, one would think that the judge would base his ruling on the patent issues and not render an opinion as to which injector he feels is superior.
If you're long (not a trader) who gives a #$%$ about whether the stock crosses it's moving averages. If the trial results are positive then patients, the company and share price will benefit and vice versa.
I'd gather most of the technical talk is by traders not investors.
Mr. Kovner is a strong supporter of Synta which is a major positive in my view.
However, I have found nothing to confirm your assertion that he is one of the most successful investors in the Biotech industry.
Please inform us of the other biotech investments Bruce has made in the past that would lead people to consider him one of the most successful biotech investors.
Then they appoint a guy who led DCTH in the ground as their new CEO. Troubling.
Synta's June Investor's Presentation states that interim analysis for GALAXY-2 is planned for 2H of 2015 and final analysis is 1H of 2016.
The stock is trending nicely in the right direction but FDA approval of Ganetespib is a long way off.